Friday, October 6, 2017: 7:00 AM-8:15 AM
At the conclusion of this session, participants will be able to:
- identify controversies in the treatment of ESBL infections.
- describe the evidence for active empiric therapy for ESBL infections.
- describe the evidence for what antibiotics should be used for definitive therapy when an ESBL infection has been identified.
Academicians, Clinicians, Fellows, Healthcare workers, Infectious diseases pediatricians, Infectious diseases physicians, Medical students and residents, Members-in-training, Pharmacists
Pediatric ID, Adult ID, Trainee
David Greenberg, MD, FIDSA, University of Texas Southwestern Medical Center
Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE
Patent, Copyright, License
Licensing agreement or royalty